Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	124.71	99.6	83.57	72.05	67.45	59.26
Revenue Growth (YoY)	36.04%	19.18%	15.99%	6.82%	13.83%	28.01%
Cost of Revenue	45.03	38.01	32.79	29.25	25.96	23.98
Gross Profit	79.68	61.59	50.78	42.8	41.49	35.27
Selling, General & Admin	54.44	47.84	51.42	56.6	64.73	51.71
Research & Development	5.94	6.02	4.96	4.83	3.83	3.42
Operating Expenses	60.38	53.86	56.38	61.43	68.56	55.13
Operating Income	19.3	7.73	-5.6	-18.63	-27.07	-19.85
Interest Expense	-	-	-	-	-0.06	-0.07
Interest & Investment Income	1.95	1.13	0.66	0	-	-
EBT Excluding Unusual Items	21.25	8.86	-4.94	-18.63	-27.13	-19.93
Other Unusual Items	-	-	-	2.09	-	-
Pretax Income	21.25	8.86	-4.94	-16.54	-27.13	-19.93
Income Tax Expense	0.82	0.31	-	-	-	-
Earnings From Continuing Operations	20.43	8.55	-4.94	-16.54	-27.13	-19.93
Net Income	20.43	8.55	-4.94	-16.54	-27.13	-19.93
Net Income to Common	20.43	8.55	-4.94	-16.54	-27.13	-19.93
Shares Outstanding (Basic)	78	76	75	70	67	61
Shares Outstanding (Diluted)	85	78	75	70	67	61
Shares Change (YoY)	10.80%	4.19%	7.54%	3.79%	10.02%	7.03%
EPS (Basic)	0.26	0.11	-0.07	-0.24	-0.40	-0.33
EPS (Diluted)	0.23	0.11	-0.07	-0.24	-0.40	-0.33
Free Cash Flow	21.15	11.95	6.97	-15.43	-24.57	-10.72
Free Cash Flow Per Share	0.25	0.15	0.09	-0.22	-0.37	-0.18
Gross Margin	63.89%	61.83%	60.76%	59.40%	61.51%	59.53%
Operating Margin	15.48%	7.76%	-6.70%	-25.85%	-40.14%	-33.51%
Profit Margin	16.38%	8.58%	-5.91%	-22.96%	-40.22%	-33.63%
Free Cash Flow Margin	16.96%	11.99%	8.34%	-21.42%	-36.43%	-18.10%
EBITDA	20.08	8.54	-4.57	-17.57	-25.96	-18.74
EBITDA Margin	16.10%	8.58%	-5.47%	-24.39%	-38.48%	-31.62%
D&A For EBITDA	0.78	0.81	1.03	1.06	1.12	1.11
EBIT	19.3	7.73	-5.6	-18.63	-27.07	-19.85
EBIT Margin	15.48%	7.76%	-6.70%	-25.85%	-40.14%	-33.51%
Effective Tax Rate	3.87%	3.44%	-	-	-	-
Advertising Expenses	-	11.1	10.3	11.4	12.5	7.4

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q